METHODS: Materials and Methods: To achieve the goal of the research, scientific publications posted in Ukrainian information and scientific databases (NRAT, OUCI) and scientometric databases Scopus, Web of Science, PubMed, MedLine, BMJ, Embase were used. The analysis of international and domestic legal documents was carried out, the sites of global international organizations, the sites of cardiology societies and Ukrainian statistical data bases were researched. The methods of content analysis, synthesis, systematization, and generalization were used.
CONCLUSIONS: Conclusions: As a result of the study, socio-economic factors that af f ect the state of pharmaceutical provision of patients with CVD (in particular, CAD) were determined. In this study, among the specif i ed socio-economic factors, the need to update the regulatory and legal security of the pharmaceutical care process attracts the most of attention. The positive impact of the use of modern drug pharmacotherapy for coronary artery disease on the budget of the health care system in clinical practice proposed by the ESC was determined.
方法:材料和方法:为实现研究目标,在乌克兰信息和科学数据库中发布的科学出版物(NRAT,OUCI)和科学计量数据库Scopus,WebofScience,PubMed,MedLine,BMJ,使用了Embase。对国际和国内法律文件进行了分析,全球国际组织的网站,研究了心脏病学会和乌克兰统计数据库的网站。内容分析法,合成,系统化,并使用了泛化。
结论:结论:作为研究的结果,影响心血管疾病患者药物供应状况的社会经济因素(特别是,CAD)被确定。在这项研究中,在特定的社会经济因素中,更新药物护理过程的监管和法律安全的需要引起了最多的关注。确定了ESC提出的现代药物药物治疗冠心病对临床实践中医疗保健系统预算的积极影响。